VRE Screening

VRE infections are associated with increased mortality, longer hospital stays and rising hospital costs. Colonization with VRE can progress to infection, and these severe adverse outcomes are an economic burden to both the hospital and the patient.2 This results in longer hospital stays (up to 6 days), increased costs ($12,766 per case) and a two-fold increase in mortality.2 A rapid, reliable VRE screening test is critical to controlling these dangerous organisms and saving lives.

product-vre

*Patent pending

Spectra™ VRE
When you need a VRE screening test with superior performance in a cost-effective package, Spectra™ VRE is the clear choice for active surveillance and screening. Spectra VRE is the first chromogenic media for the 24-hour detection of gastrointestinal colonization of vancomycin-resistant Enterococcus (VRE). Spectra VRE allows differentiation of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis.

  • Rapidly and economically detects colonization of Vancomycin-Resistant Enterococcus (VRE) colonization
  • Aids in the prevention and controls the spread of vancomycin resistance in healthcare settings
  • Correctly classifies patients whether positive or negative
  • Provides superior results in a selective and differential chromogenic medium
Product InformationPackagingREF
Spectra™ VRE10 Plates/PkR01830
100 Plates/PkR01832

References

  1. Hidron, A.I., et. al. Infection Control and Epidemiology; 2008; 29:996-1011.
  2. Carmeli, Y., et. al. Archives of Internal Medicine; Volume 162; October 28, 2002.

Make Your Move Before
Healthcare-Associated Infections Do.

Prevention starts with preparation. That's why we developed a total solution for MRSA screening,
C. dIff testing, and VRE screening. To help control the spread, these Healthcare-Associated Infection control products are designed to deliver rapid, reliable results. For your hospital, that means better patient management. For your patients, it means everything.

REQUEST INFORMATION

Cost Analzyer